Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 113,318 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 113,318 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the transaction, the chief executive officer directly owned 818,938 shares in the company, valued at approximately $102,498,280.08. This trade represents a 12.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Trading Up 1.7%

Shares of Twist Bioscience stock opened at $125.21 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $125.66. The stock has a 50 day moving average price of $92.54 and a two-hundred day moving average price of $66.21. The stock has a market capitalization of $7.85 billion, a PE ratio of -56.40 and a beta of 2.14.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period in the previous year, the company earned $0.33 earnings per share. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new position in Twist Bioscience during the second quarter worth about $1,939,000. Westpac Banking Corp purchased a new stake in Twist Bioscience in the 2nd quarter valued at about $628,000. William Blair Investment Management LLC purchased a new stake in Twist Bioscience in the 2nd quarter valued at about $223,722,000. EP Wealth Advisors LLC bought a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $492,000. Finally, Ieq Capital LLC bought a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $5,258,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Leerink Partners set a $110.00 price objective on shares of Twist Bioscience in a report on Thursday, July 16th. Canaccord Genuity Group raised their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Barclays lifted their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Robert W. Baird boosted their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Finally, TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.